检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

2022-RA-858-ESGO Benefit of bevacizumab according to CA125 decline kinetic in first-line high grade serous ovarian carcinoma (HGSOC) patients in real-life setting

Ondine Becker,Marion Chevrier,Laurence Gladieff,Florence Joly, Philippe Toussaint,Anne Floquet,Christophe Pomel,Helene Costaz,Maria Kfoury,Thibault de la Motte Rouge,Renaud Sabatier,Cecile Loaec,Eric Leblanc,Frederic Marchal,Pierre-Emmanuel Colombo,Emmanuel Barranger,Olivier Colomban, Lise Bosquet,Manuel Rodrigues,Benoit You

Ovarian cancer（2022）

引用 0|浏览8
暂无评分
关键词
serous ovarian carcinoma,bevacizumab,ca125 decline kinetic,first-line,real-life
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要